Mass General - Division of Clinical Research

(participants with AVP-D): AVP-D diagnosed in clinic using standard of care diagnostic tools; Stable pituitary hormone replacement (no change in dose of hormone replacement in six weeks prior to baseline); If on estrogen/progestin, female participants agree to stop for at least 6 weeks prior to Main study visits; English language proficiency. Inclusion criteria (participants with hypopituitary disease): Hypopituitary disease diagnosis; If receiving pituitary hormone replacement, no change in dose in six weeks prior to baseline); If on estrogen/progestin, participants agree to stop for at least 6 weeks prior to Main study visits; English language proficiency.

(all participants): History of pulmonary embolism or unprovoked deep venous thrombosis; History of breast/endometrial cancer as well as current therapies on estrogen modulators/blockers (i.e., tamoxifen, raloxifene, aromatase inhibitors); History of stroke, transient ischemic attack, myocardial infarction, angina pectoris, or peripheral arterial disease; Pregnancy or breastfeeding within the last 8 weeks; Medication changes within 2 weeks of enrollment or within 5 half-lives of the respective medication; History of stage 3 chronic kidney disease or cirrhosis; Any significant illness or condition that the investigator determines could interfere with study participation, data collection or safety.; Active tobacco smoking or nicotine patch use; Psychosis or active suicidality.